WO2000046248A1 - Use of agonists or antagonists of mip-3a in therapy - Google Patents
Use of agonists or antagonists of mip-3a in therapy Download PDFInfo
- Publication number
- WO2000046248A1 WO2000046248A1 PCT/US2000/000511 US0000511W WO0046248A1 WO 2000046248 A1 WO2000046248 A1 WO 2000046248A1 US 0000511 W US0000511 W US 0000511W WO 0046248 A1 WO0046248 A1 WO 0046248A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mip
- cells
- cell
- ccr6
- leu
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Definitions
- the invention relates generally to methods of using various chemokine related compositions, more particularly, to methods of treating skin diseases or conditions associated with misregulation of the chemokine MIP-3 ⁇ , a ligand for the CCR6 chemokine receptor.
- the immune system consists of a wide range of distinct cell types, each with important roles to play. See Paul (ed. 1997) Fundamental Immunology 4th ed., Raven Press, New York.
- the lymphocytes occupy central stage because they are the cells that determine the specificity of immunity, and it is their response that orchestrates the effector limbs of the immune system.
- Two broad classes of lymphocytes are recognized: the B lymphocytes, which are precursors of antibody secreting cells, and the T (thymus-dependent) lymphocytes.
- T lymphocytes express important regulatory functions, such as the ability to help or inhibit the development of specific types of immune response, including antibody production and increased microbicidal activity of macrophages .
- Other T lymphocytes are involved m direct effector functions, such as the lysis of virus infected-cells or certain neoplastic cells.
- the chemokmes are a large and diverse superfamily of proteins. The superfamily is subdivided into two classical branches, based upon whether the first two cystemes m the chemokine motif are adjacent (termed the "C-C” branch) , or spaced by an intervening residue (“C-X-C”) .
- C-C chemokine motif
- C-X-C intervening residue
- a more recently identified branch of chemokmes lacks two cystemes the corresponding motif, and is represented by the chemokmes known as lymphotactms .
- Another recently identified branch has three intervening residues between the two cystemes, e.g., CX3C chemokmes. See, e.g., Schall and Bacon (1994) Current Opinion m Immunology 6:865-873; and Bacon and Schall (1996) Int.
- the present invention is based, part, upon the surprising discovery that the MIP-3 chemokine is expressed m inflamed skm cells.
- the chemokine is the ligand for the CCR6 receptor. See Greaves, et al . (1997) J. Expt ' 1 Med. 186:837- 844. Both the ligand and receptor are expressed at essentially undetectable levels m normal skm, while both are highly upregulated m inflamed skm.
- the present invention provides methods of modulating migration of a cell within or to the skm of a mammal comprising administering to the mammal an effective amount of: an antagonist of MIP-3 ; an agonist of MIP-3 ⁇ , and antagonist of CCR6 ; or an agonist of CCR6.
- the migration is withm the skm; or may be chemotactic or chemokmetic .
- the administering is systemic, local, topical, subcutaneous, mtracutaneous , or transdermal .
- the cell is a T cell, B cell, dendritic cell, or dendritic cell precursor.
- the cell is a T cell, or moves into the dermal and/or epidermal layers of the skm.
- the administering is of an antagonist of MIP-3 .
- the antagonist is selected from: a mutem of natural MIP-3 ⁇ ; an antibody which neutralizes MIP-3 ⁇ ; or an antibody which binds to CCR6.
- the mammal is subject to a skm disease or condition, including one selected from cancer, cancer metastasis, skm transplant, or skm graft.
- the antagonist is administered m combination with an antibiotic, antifungal, antiviral, or analgesic; or may be with an immune suppressive therapeutic, anti- inflammatory drug, growth factor, or immune adjuvant.
- the administering is with a primate MIP-3 ⁇ .
- the modulating is attracting the cell, e.g., to a site of cutaneous lesion.
- the primate MIP-3 ⁇ may be administered m combination with an antibiotic, antifungal, antiviral, or analgesic; or with a vasodilator, growth factor, cytok e, anti- inflammatory drug, or immune adjuvant.
- the invention provides a method of purifying a population of cells, the method comprising contacting the cells with MIP-3 ⁇ , thereby resulting m the identification of cells expressing a receptor for MIP-3 .
- the receptor is CCR6 , or the contacting results m specific migration of the cells to a site for purification, e.g., through pores of a membrane.
- the invention is based, m part, on the surprising discovery that the chemokine MIP-3 ⁇ has been implicated m roles m skm immunity.
- MIP-3 ⁇ has been identified as a ligand for the chemokine receptor designated CCR6.
- CCR6 chemokine receptor
- Both MIP-3 ⁇ and CCR6 expression are undetectable m normal skm, while both are highly upregulated m inflamed skm samples .
- the skm consists of a surface layer of epithelium called the epidermis and an underlying layer of connective tissue called the dermis. Under the dermis is a layer which contains large amounts of adipose tissue, the hypodermis.
- the skm serves a variety of functions, and variations m the character of the dermis and epidermis occur according to functional demands.
- the appendages of the skm, hair, nails, and sweat and sebaceous glands, are such local specializations of the epidermis. Together, the skm and its appendages form the integument. See, e.g., Fitzpatrick, et al . (eds. 1993) Dermatology m General Medicine 4th ed., McGraw-Hill, NY; Bos (ed. 1989) Skm Immune System CRC Press, Boca Raton, FL; Callen (1996) General Practice Dermatology Appleton and Lange; Rook, et al . (eds.
- the epidermis consists of many different cell types m various proportions. The most prevalent cell type is keratmocytes, which make up some 95% of the cells. Cells m the 1-2% range include melanocytes and Langerhans cells. The Langerhans cells are particularly important because they trap antigens that have penetrated the skm, and transport antigens to regional lymph nodes. A small population of ⁇ T cells can also reside m the epidermis.
- the dermis varies m thickness m different regions of the body. It is tough, flexible, and highly elastic, and consists of a feltwork of collagen fibers with abundant elastic fibers.
- the connective tissue is arranged into deep reticular and superficial papillary layers.
- the chemokmes are a sub- family of chemoattractant cytokmes that were classically characterized by their ability to mediate leukocyte trafficking or migration by binding to specific G-protem-lmked seven transmembrane spanning receptors, or GPCRs . Chemokmes are divided into four groups based on the primary sequence of the first two cystemes : the CXC, CC, C, and CX3C families. The CXC and C families are effective predominantly on neutrophils and lymphocytes, respectively. The CC chemokmes are preferentially effective on macrophages, lymphocytes, and eosmophils.
- the chemokine MIP-3 ⁇ from human, mouse, and rat, has been described earlier. See, e.g., human, GenBank HSU77035; mouse, GenBank AF099052; rat, GenBank U90447; Li and Adams, WO 94-US9484; and Wilde, et al . WO 9616979; each of which is incorporated herein by reference for all purposes.
- the sequences are provided m Table 1.
- Table 1 A primate, human, MIP-3 ⁇ , nucleic acid sequence (SEQ ID NO: 1) and amino acid sequence (SEQ ID NO : 2) . Coding sequence begins at about nucleotide 1 and ends at about 288; CC motif at amino acid residues 6-7.
- a signal sequence is indicated, but based upon related genes; slightly different processing may occur in different cell types .
- atg tgc tgt ace aag agt ttg etc ctg get get ttg atg tea gtg ctg 48 Met Cys Cys Thr Lys Ser Leu Leu Leu Ala Ala Leu Met Ser Val Leu -25 -20 -15 eta etc cac etc tgc ggc gaa tea gaa gca gca age aac ttt gac tgc 96 Leu Leu His Leu Cys Gly Glu Ser Glu Ala Ala Ser Asn Phe Asp Cys -10 -5 -1 1 5 tgt ctt gga tac aca gac cgt att ctt cat cct aaaa ttt att gtg ggc 144 Cys Leu Gly Tyr Thr Asp Arg lie Leu
- Table 1 (continued) : A murine, mouse, MIP-3 ⁇ chemokine nucleic acid sequence (SEQ ID NO : 3) and corresponding amino acid sequence (SEQ ID NO: 4).
- SignalP software predicts a cleavage between Ala(-l) and Serl; but the actual cleavage may be on either side by a residue or so.
- Table 1 (continued) : A murine, rat, MIP-3 ⁇ chemokine nucleic acid sequence (SEQ ID NO: 5) and corresponding amino acid sequence (SEQ ID NO: 6) .
- SignalP software predicts a cleavage between Ala(-l) and Alal; but the actual cleavage may be on either side by a residue or so.
- Nucleotide 579 may be A, C, G, or T, and the codon may code for His or Gin.
- memory/effector lymphocytes can access non-lymphoid effector sites and display restricted, often tissue-selective, migration behavior. This results m the presence of such lymphocytes m the peripheral tissues, e.g., outside of the lymphatic and blood volume.
- Both human and mouse MIP-3 ⁇ are detected m lymph nodes, appendix, PBL, fetal liver, fetal lung, and various cell lines. See, e.g., Rossi, et al . (1997) . Immunol . 158:1033- 1036; Hieshima, et al . (1997) J. Biol . Chem. 272:5846-5853; Baba, et al . (1997) J. Biol . Chem. 272:14893-14898; and Imai , et al. (1997) J. Biol. Chem. 272:15036-15042.
- the expression m the Langerhans islets suggests a role m skm functions.
- MIP-3 ⁇ as a product of activated monocytes, and is preferentially expressed m inflamed tissue. This distribution would suggest that MIP-3 ⁇ may have a role m attracting memory T cells, and skm dendritic cells (Langerhans cells) and their precursors. These results suggest an important role for MIP-3 ⁇ m recruitment of T cells and dendritic cells to peripheral cutaneous sites.
- Chemokine receptors are members of the G protein coupled receptor family. See, e.g., Yoshie, et al . (1997) J. Leukoc . Biol . 62:634-644. CCR6 expression has been reported m Greaves, et al . (1997) J. Expt ' 1 Med.
- CCR6 was expressed on memory T cells, including most ⁇ 4 ⁇ 7 memory cells and cutaneous lymphocyte-associated antigen expressing cells, and on B cells. Chemotaxis of T cells to MIP-3 ⁇ was limited to memory cells. See Liao, et al . (1998) J . Immunol . 162:186-194. Antiserum detected CCR6 on CD34+ bone marrow derived dendritic cells . Having identified the MIP-3 ⁇ as a skm related chemokine, it will find use m affecting medical abnormalities of the skm.
- sk disorders involving the immune system include psoriasis, skm cancers, carcinomas, inflammation, allergies, dermatitis, wound healing, infections (both microbial and parasitic), and many others. See, e.g., The Merck Manual , particularly the chapter on dermatologic disorders. These therapeutics may have useful effects on growth or health of appendages of the skm, including, e.g., hair, nails, and sweat and sebaceous glands.
- Psoriasis is a chronic inflammatory skm disease that is associated with hyperplastic epidermal keratmocytes and infiltrating mononuclear cells, including T cells, neutrophils and macrophages . Because of this highly mixed inflammatory picture and the resulting complex interrelationships between these different cells, it has been very difficult to dissect the mechanisms that underlie the induction and progression of the disease.
- Dermatitis is a superficial inflammation of the skm, characterized by vesicles (when acute), redness, edema, oozing, crusting, scaling, and/or itching. See, e.g., Lepoittevm (ed. 1998) Allergic Contact Dermatitis: The Molecular Basis Sprmger-Verlag; Rietschel and Fowler (eds. 1995) Fisher's Contact Dermatitis Lippmcott; and Rycroft, et al . (eds. 1994) Textbook of Contact Dermatitis Sprmger- Verlag.
- the term eczematous dermatitis is often used to refer to a vesicular dermatitis. Dermatitis may accompany various immune deficiency conditions or diseases, inborn metabolic disorders, or nutritional deficiency diseases. Certain of the symptoms of such conditions may be treated using the present invention.
- Pruritus is a sensation that the patient attempts to relieve by scratching. See, e.g., Fleischer and Fleischer (1998) The Clinical Management of Itching: Therapeutic Protocols for Pruritus Parthenon. Many parasitic or infectious conditions may result m those symptoms, which conditions may be cleared by proper reactivation or suppression of immune functions the skm. Likewise with various allergic or other immune reactions to exposure to various allergic or inflammatory antigens. II. Chemokine Agonists and Antagonists
- Mammalian MIP-3 chemokmes were described previously m USSN 08/887,977, which describes various migratory assays. Various agonists and antagonists of the natural ligands can be produced. The migration assays may take advantage of the movement of cells through pores m membranes. Chemotaxis may be measured thereby. Alternatively, chemokmetic assays may be developed, which measure the induction of kinetic movement, not necessarily relative to a gradient, per se . A. MIP-3 ⁇ and variants
- MIP-3 ⁇ agonists will exhibit some or all of the signaling functions of MIP-3 ⁇ , e.g., binding, inducing a Ca++ flux, and chemoattractmg appropriate receptor bearing cells.
- Various mammalian MIP-3 ⁇ sequences may be evaluated to determine what residues are conserved across species, suggesting what residues may be changed without dramatic effects on biological activity. Alternatively, conservative substitutions are likely to retain biological activity, thus leading to variant forms of the chemokine which will retain agonist activity. Standard methods for screening mutant or variant MIP-3 ⁇ polypeptides will determine what sequences will be useful therapeutic agonists.
- nucleic acid expression methods may be applied. For example, m skm graft contexts, it may be useful to transfect the grafts with nucleic acids which will be expressed, as appropriate.
- Various promoters may be operably linked to the gene, thereby allowing for regulated expression.
- Antisense constructs may prevent expression of the ligand or receptor.
- antagonist activity may be tested or screened for. Tests for ability to antagonize chemoattractant activity can be developed using assays as described below.
- Various ligand homologs can be created which retain receptor binding capacity, but lack signaling capability, thus serving as competitive binding molecules.
- Small molecules may also be screened for ability to antagonize MIP-3 ⁇ function, e.g., chemoattraction, receptor binding, Ca++ flux, and other effects mediated by MIP-3 ⁇ .
- MIP-3 ⁇ chemoattraction, receptor binding, Ca++ flux, and other effects mediated by MIP-3 ⁇ .
- the present invention provides for the use of an antibody or binding composition which specifically binds to MIP-3 ⁇ , preferably mammalian, e.g., primate, human, cat, dog, rat, or mouse, and neutralizes the ability of the chemokine to mediate its signal.
- Antibodies can be raised to various MIP-3 proteins, including individual, polymorphic, allelic, strain, or species variants, and fragments thereof, either m their naturally occurring (full-length) forms or m their recombinant orms. Additionally, antibodies can be raised to MIP-3 ⁇ or polypeptides m both their native (or active) forms or m their inactive, e.g., denatured, forms, which may neutralize ligand capacity to mediate its signal. Antibodies may block the interaction of the ligand with its receptor.
- receptor antagonists may be produced by making antibodies which bind to the receptor and block ligand binding. With the identification of the CCR6 as a receptor for the cytokme, antibodies to the receptor may be selected for those which block the binding of, or signaling induced by, ligand.
- a number of lmmunogens may be selected to produce antibodies specifically reactive, or selective for binding, with MIP-3 ⁇ or CCR6 proteins.
- Recombinant protein is a preferred immunogen for the production of monoclonal or polyclonal antibodies.
- Naturally occurring protein from appropriate sources, e.g., primate, rodent, etc., may also be used either m pure or impure form.
- Synthetic peptides, made using the MIP-3 ⁇ or CCR6 protein sequences described herein, may also be used as an immunogen for the production of antibodies.
- Recombinant protein can be expressed and purified m eukaryotic or prokaryotic cells as described, e.g., m Coligan, et al . (eds.
- an immunogen preferably a purified protein
- an adjuvant e.g., a human immunogen
- animals are immunized with the mixture.
- the animal's immune response to the immunogen preparation is monitored by taking test bleeds and determining the titer of reactivity to, e.g., the MIP-3 , protein or polypeptide of interest.
- titer of reactivity e.g., the MIP-3 , protein or polypeptide of interest.
- blood is collected from the animal and antisera are prepared. Further fractionation of the antisera to enrich for antibodies reactive to the protein can be performed, if desired. See, e.g., Harlow and Lane Antibodies, A Laboratory Manual; or
- Monoclonal antibodies may be obtained by various techniques familiar to those skilled m the art. Typically, spleen cells from an animal immunized with a desired antigen are immortalized, commonly by fusion with a myeloma cell. See, Kohler and Milste (1976) Eur . J. Immunol. 6:511-519.
- DNA sequences which encode a monoclonal antibody or a binding fragment thereof by screening a DNA library from human B cells according, e.g., to the general protocol outlined by Huse, et al. (1989) Science 246:1275-1281.
- Antibodies or binding compositions, including binding fragments and single chain versions, against predetermined fragments of MIP-3 ⁇ or CCR6 polypeptides can be raised by immunization of animals with conjugates of the fragments with carrier proteins as described above.
- Monoclonal antibodies are prepared from cells secreting the desired antibody. These antibodies can be screened for binding to normal or defective
- MIP-3 ⁇ protein or screened for capacity to block cell MIP-3 ⁇ mediated chemoattraction or chemokmetic activity.
- These monoclonal antibodies will usually bind with at least a Q of about 1 mM, more usually at least about 300 ⁇ M, typically at least about 10 ⁇ M, more typically at least about 30 ⁇ M, preferably at least about 10 ⁇ M, and more preferably at least about 3 ⁇ M or better.
- mAbs monoclonal antibodies
- mammalian hosts such as mice, rodents, primates, humans, etc.
- Description of techniques for preparing such monoclonal antibodies may be found m, e.g., Stites, et al .
- hybrid cell or "hybridoma” that is capable of reproducing vitro.
- the population of hyb ⁇ domas is then screened to isolate individual clones, each of which secrete a single antibody species to the immunogen.
- the individual antibody species obtained are the products of immortalized and cloned single B cells from the immune animal generated m response to a specific site recognized on the lmmunogenic substance.
- polypeptides and antibodies of the present invention may be used with or without modification, including chimeric or humanized antibodies. Frequently, the polypeptides and antibodies will be labeled by joining, either covalently or non-covalently, a substance which provides for a detectable signal.
- labels and conjugation techniques are known and are reported extensively m both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, chemilummescent moieties, magnetic particles, and the like. Patents teaching the use of such labels include U.S. Patent Nos.
- Antibody binding compounds can have significant diagnostic or therapeutic value. They can be useful as non-neutraliz g binding compounds and can be coupled to toxins or radionuclides so that when the binding compound binds to the antigen, a cell expressing it, e.g., on its surface, is killed. Further, these binding compounds can be conjugated to drugs or other therapeutic agents, either directly or indirectly by means of a linker, and may effect drug targeting . C. Other Molecules
- Antibodies are merely one form of specific binding compositions.
- Other binding compositions which will often have similar uses, include molecules that bind with specificity to MIP-3 ⁇ receptor, e.g., CCR6 , m a binding partner-binding partner fashion, an antibody-antigen interaction, or m a natural physiologically relevant protem- protein interaction, either covalent or non-covalent, e.g., proteins which specifically associate with MIP-3 ⁇ receptor protein.
- the molecule may be a polymer, or chemical reagent.
- a functional analog may be a protein with structural modifications, or may be a structurally unrelated molecule, e.g., which has a molecular shape which interacts with the appropriate binding determinants.
- Drug screening using antibodies or MIP-3 ⁇ or fragments thereof can be performed to identify compounds having binding affinity to MIP-3 ⁇ , or can block or simulate the natural interaction with ligand. Subsequent biological assays can then be utilized to determine if the compound has intrinsic blocking activity and is therefore an antagonist. Likewise, a compound having intrinsic stimulating activity can signal to the cells via the MIP-3 ⁇ pathway and is thus an agonist m that it simulates the activity of a ligand. Mutem antagonists may be developed which maintain receptor binding but lack signaling.
- receptor specific binding molecules are provided, also included are small molecules identified by screening procedures. In particular, it is well known m the art how to screen for small molecules which interfere, e.g., with ligand binding to the receptor, often by specific binding to the receptor and blocking of binding by natural ligand. See, e.g., meetings on High Throughput Screening, International Business Communications, Southborough, MA 01772-1749. Such molecules may compete with natural ligands, and selectively bind to the MIP-3 ⁇ or CCR6
- Immunoassays are valuable m diagnosing a disease or disorder associated with MIP-3 ⁇ imbalance or pathology.
- Qualitative or quantitative measurement of a particular protein can be performed by a variety of immunoassay methods.
- immunoassay methods For a review of immunological and immunoassay procedures m general, see Stites and Terr (eds. 1991) Basic and Clinical Immunology (7th ed.) .
- the immunoassays of the present invention can be performed m many configurations, which are reviewed extensively m, e.g., Maggio (ed.
- the present invention provides various skm related diseases as conditions susceptible to analysis or diagnosis by evaluating MIP-3 ⁇ and/or CCR6.
- MIP-3 ⁇ and/or CCR6 For example, the likelihood of skm rejection a graft situation would be evaluated by the numbers or types of MIP-3 ⁇ or CCR6 bearing cells present.
- Prophylactic downregulation may be useful to prevent the recruitment of dermal T or NK cells.
- Response to various skm tumors may be evaluated by the presence or absence of MIP-3 ⁇ and/or CCR6 bearing cells.
- Immunoassays for measurement of MIP-3 ⁇ proteins or peptides can be performed by a variety of methods known to those skilled m the art.
- immunoassays to measure the protein can be either competitive or noncompetitive binding assays.
- the sample to be analyzed competes with a labeled analyte for specific binding sites on a capture agent bound to a solid surface.
- the capture agent is an antibody specifically reactive with MIP-3 ⁇ proteins produced as described above.
- the concentration of labeled analyte bound to the capture agent is inversely proportional to the amount of free analyte present the sample.
- the MIP- 3 ⁇ protein present m the sample competes with labeled protein for binding to a specific binding agent, e.g., an antibody specifically reactive with the MIP-3 protein.
- the binding agent may be bound to a solid substrate or surface to effect separation of bound labeled protein from the unbound labeled protein.
- the competitive binding assay may be conducted m liquid phase and a variety of techniques known m the art may be used to separate the bound labeled protein from the unbound labeled protein. Following separation, the amount of bound labeled protein is determined. The amount of protein present the sample is inversely proportional to the amount of labeled protein binding.
- a homogeneous immunoassay may be performed m which a separation step is not needed.
- the label on the protein is altered by the binding of the protein to its specific binding agent.
- This alteration m the labeled protein results m a decrease or increase m the signal emitted by label, so that measurement of the label at the end of the immunoassay allows for detection or quantitation of the protein.
- MIP-3 ⁇ proteins may also be determined by a variety of noncompetitive immunoassay methods. For example, a two-site, solid phase sandwich immunoassay may be used. In this type of assay, a binding agent for the protein, e.g., an antibody, is attached to a solid support.
- a second protein binding agent which may also be an antibody, and which binds the protein at a different site, is labeled. After binding at both sites on the protein has occurred, the unbound labeled binding agent is removed and the amount of labeled binding agent bound to the solid phase is measured. The amount of labeled binding agent bound is directly proportional to the amount of protein m the sample .
- Western blot analysis can be used to determine the presence of MIP-3 ⁇ or CCR6 proteins m a sample. Electrophoresis is carried out, for example, on a tissue sample suspected of containing the protein. Following electrophoresis to separate the proteins, and transfer of the proteins to a suitable solid support, e.g., a nitrocellulose filter, the solid support is incubated with an antibody reactive with the protein. This antibody may be labeled, or alternatively may be detected by subsequent incubation with a second labeled antibody that binds the primary antibody.
- the immunoassay formats described above may employ labeled assay components. The label may be coupled directly or indirectly to the desired component of the assay according to methods well known m the art. A wide variety of labels and methods may be used.
- Non- radioactive labels include ligands which bind to labeled antibodies, fluorophores , chemilummescent agents, enzymes, and antibodies which can serve as specific binding pair members for a labeled ligand.
- the choice of label depends on sensitivity required, ease of conjugation with the compound, stability requirements, and available instrumentation.
- Antibodies reactive with a particular protein can also be measured by a variety of immunoassay methods.
- mice are preferably used.
- Skm e.g., Langerhans
- cell counts are made prior to and at various time points after administration of a bolus of the candidate agonist or antagonist.
- Levels are analyzed m various samples, e.g., blood, serum, nasal or pulmonary lavages, or tissue biopsy staining.
- a successful depleting mAb or binding composition will significantly lower the level of CCR6 bearing cells. Such may be at least about 10%, preferably at least about 20%, 30%, 50%, 70%, or more.
- Evaluation of antibodies can be performed m other animals, e.g., humans using various methods. For example, blood samples are withdrawn from patients suffering from a skm related disease or disorder before and after treatment with a candidate mAb.
- the present invention provides means to purify desired skm cell subsets.
- the chemoattractive or chemokmetic effects on those cells can be the basis of purification methods. Methods exist for selective migration and recovery of cells to or from the chemokine, e.g., through porous membrane, or to various locations m a culture. Other methods exist to selectively separate cells of particular shapes from others. Alternatively, labeling can be used to FACS sort cells which specifically bind the chemokine. Populations of substantially homogeneous Langerhans or skm derived cells will have important utility research or therapeutic environments.
- MIP-3 ⁇ is likely to have functional effects on CCR6 bearing subsets of cells, e.g., T and B cells and precursors
- other cells which may also be responsive include dendritic cells or granulocytes , e.g., neutrophils and/or eosmophils, or their precursors. Effects on various cell types may be indirect, as well as direct. A statistically significant change m the numbers of cells will typically be at least about 10%, preferably 20%, 30%, 50%, 70%, 90%, or more. Effects of greater than 100%, e.g., 130%, 150%, 2X, 3X, 5X, etc., will often be desired. The effects may be specific m causing chemotaxis to specific points, or may be chemokmetic, m inducing general movement of cells, but not necessarily m a specific direction, e.g., of concentration gradient.
- the present invention will be useful m the treatment of medical conditions or diseases associated with immunological conditions of the skm. See, e.g., Bos (ed. 1990) Skm Immune System CRC Press, Boca Raton, FL; Fitzpatrick, et al . (eds. 1993) Dermatology m General Medicine (4th ed.) McGraw-Hill, NY; Rook, et al . (eds. 1998) Textbook of Dermatology Blackwell; Habifor and Habie (1995) Clinical Dermatology: A Color Guide to Diagnosis and Therapy Mosby; Grob (ed. 1997) Epidemiology, Causes and Prevention of Skm Diseases
- agonists or antagonists described may be combined with other treatments of the medical conditions described herein, e.g., an antibiotic, antifungal, antiviral, immune suppressive therapeutic, immune adjuvant, analgesic, anti -inflammatory drug, growth factor, cytokme, vasodilator, or vasoconstrictor.
- the CCR6 receptor appears to be preferentially expressed on CD4+ memory T cells.
- Its ligand, MIP-3 ⁇ is an inflammatory chemokine expressed by cellular constituents of the skm, whose expression is mducible after stimulation with T cell-derived promflammatory meidators such as IFN- ⁇ and IL- 17.
- T cell-derived promflammatory meidators such as IFN- ⁇ and IL- 17.
- CD4+ memory T cell mediated skm conditions are therapeutic targets of the antagonists, e.g., psoriasis, atopic dermatitis, contact dermatitis, SLE, and lichen ruber planus .
- Preferred combination therapies include the MIP-3 ⁇ reagent with various anti -inflammatory agents, such as topical, transdermal, or systemic steroids or corticosteroids .
- Systemic, topical, transdermal, or systemic retmoid or retmoid-like compounds, or vitamin D analogs may be administered with the MIP-3 therapeutics.
- various forms of UV light may be used m combination with these therapeutics, e.g., ultraviolet A, ultraviolet B, or narrow bands of UVB .
- the MIP-3 ⁇ ligands would be expected to signal specifically to the cell types expressing their receptor.
- compositions including, e.g., MIP-3 ⁇
- the material is admixed with a pharmaceutically acceptable carrier or excipient which is preferably inert.
- a pharmaceutically acceptable carrier or excipient which is preferably inert.
- Preparation of such pharmaceutical compositions is known m the art, see, e.g., Remington ' s Pharmaceutical Sciences and U.S. Pharmacopeia: National Formulary, Mack Publishing Company, Easton, PA (1984) .
- therapeutic compositions are sterile.
- MIP-3 ⁇ antagonist compositions can be prepared.
- Agonists, e.g., natural ligand, or antagonists, e.g., antibodies or binding compositions are normally administered parenterally, preferably intravenously.
- Such protein or peptide antagonists may be lmmunogenic they are preferably administered slowly, either by a conventional IV administration set or from a subcutaneous depot, e.g. as taught by Tomasi, et al . , U.S. patent 4,732,863.
- the administration may be topical, transdermal, mtradermal , subcutaneous, or even systemic.
- the therapeutics When administered parenterally the therapeutics will be formulated m a unit dosage mjectable form (solution, suspension, emulsion) m association with a pharmaceutically acceptable parenteral vehicle.
- a pharmaceutically acceptable parenteral vehicle Such vehicles are inherently nontoxic and nontherapeutic .
- the antagonist may be administered m aqueous vehicles such as water, saline, or buffered vehicles with or without various additives and/or diluting agents.
- a suspension such as a zmc suspension, can be prepared to include the peptide.
- a suspension can be useful for subcutaneous (SQ) , mtradermal (ID), or intramuscular (IM) injection.
- SQ subcutaneous
- ID mtradermal
- IM intramuscular
- the proportion of therapeutic entity and additive can be varied over a broad range so long as both are present m effective amounts.
- the therapeutic is preferably formulated m purified form substantially free of aggregates, other proteins, endotoxms, and the like, at concentrations of about 5 to 30 mg/ml , preferably 10 to 20 mg/ml.
- the endotoxm levels are less than 2.5 EU/ml .
- an administration regimen for a therapeutic agonist or antagonist depends on several factors, including the serum or tissue turnover rate of the therapeutic, the immunogenicity of the therapeutic, or the accessibility of the target cells.
- an administration regimen maximizes the amount of therapeutic delivered to the patient consistent with an acceptable level of side effects. Accordingly, the amount of therapeutic delivered depends m part on the particular agonist or antagonist and the severity of the condition being treated.
- Guidance m selecting appropriate doses of antibodies is found m the literature on therapeutic uses, e.g. Bach et al . , chapter 22, m Ferrone, et al . (eds. 1985) Handbook of Monoclonal Antibodies Noges Publications, Park Ridge, NJ; and Russell, pgs. 303-357, and Smith et al . , pgs. 365-389, m Haber, et al . (eds. 1977) Antibodies m Human Diagnosis and Therapy Raven Press, New York, NY.
- Determination of the appropriate dose is made by the clinician, e.g., using parameters or factors known the art to affect treatment or predicted to affect treatment.
- the dose begins with an amount somewhat less than the optimum dose and it is increased by small increments thereafter until the desired or optimum effect is achieved relative to any negative side effects.
- Numbers of CCR6 bearing cells m defined samples might be important indicators of when an effective dose is reached.
- an antibody or binding composition thereof that will be used is derived from the same species as the animal targeted for treatment, thereby minimizing a humoral response to the reagent.
- the total weekly dose ranges for antibodies or fragments thereof, which specifically bind to MIP-3 ⁇ range generally from about 1 ng, more generally from about 10 ng, typically from about 100 ng; more typically from about 1 ⁇ g, more typically from about 10 ⁇ g, preferably from about 100 ⁇ g, and more preferably from about 1 mg per kilogram body weight. Although higher amounts may be more efficacious, the lower doses typically will have fewer adverse effects. Generally the range will be less than 100 mg, preferably less than about 50 mg, and more preferably less than about 25 mg per kilogram body weight.
- the weekly dose ranges for antagonists range from about 10 ⁇ g, preferably at least about 50 ⁇ g, and more preferably at least about 100 ⁇ g per kilogram of body weight. Generally, the range will be less than about 1000 ⁇ g, preferably less than about 500 ⁇ g, and more preferably less than about 100 ⁇ g per kilogram of body weight. Dosages are on a schedule which effects the desired treatment and can be periodic over shorter or longer term. In general, ranges will be from at least about 10 ⁇ g to about 50 mg, preferably about 100 ⁇ g to about 10 mg per kilogram body weight .
- Hourly dose ranges for mutems range from at least about 10 ⁇ g, generally at least about 50 ⁇ g, typically at least about 100 ⁇ g, and preferably at least 500 ⁇ g per hour. Generally the dosage will be less than about 100 mg, typically less than about 30 mg, preferably less than about 10 mg, and more preferably less than about 6 mg per hour. General ranges will be from at least about 1 ⁇ g to about 1000 ⁇ g, preferably about 10 ⁇ g to about 500 ⁇ g per hour.
- transplant or skm grafts may involve the administration of the therapeutics m different forms.
- the tissue may be immersed m a sterile medium containing the therapeutic resulting m a prophylactic effect on cell migration soon after the graft is applied.
- the present invention also provides for administration of MIP-3 antibodies or binding compositions m combination with known therapies, e.g., steroids, particularly glucocorticoids, which alleviate the symptoms associated with excessive inflammatory responses.
- Daily dosages for glucocorticoids will range from at least about 1 mg, generally at least about 2 mg, and preferably at least about 5 mg per day. Generally, the dosage will be less than about 100 mg, typically less than about 50 mg, preferably less than about 20 mg, and more preferably at least about 10 mg per day. In general, the ranges will be from at least about 1 mg to about 100 mg, preferably from about 2 mg to 50 mg per day.
- an effective amount means an amount sufficient to effect a desired response, or to ameliorate a symptom or sign of the skm condition.
- Typical mammalian hosts will include mice, rats, cats, dogs, and primates, including humans.
- An effective amount for a particular patient may vary depending on factors such as the condition being treated, the overall health of the patient, the method, route, and dose of administration and the severity of side affects.
- the effect will result m a change m quantitation of at least about 10%, preferably at least 20%, 30%, 50%, 70%, or even 90% or more.
- an effective amount is m ratio to a combination of components and the effect is not limited to individual components alone.
- An effective amount of therapeutic will modulate the symptoms typically by at least about 10%; usually by at least about 20%; preferably at least about 30%; or more preferably at least about 50%.
- modulation of migration will mean that the migration or trafficking of various cell types is affected. Such will result m, e.g., statistically significant and quantifiable changes m the numbers of cells being affected. This may be an increase or decrease the numbers of target cells being attracted withm a time period or target area.
- the present invention provides reagents which will find use m therapeutic applications as described elsewhere herein, e.g., m the general description for treating disorders associated with skm conditions. See, e.g., Berkow (ed.) The Merck Manual of Diagnosis and Therapy, Merck & Co., Rahway, N.J.; Thorn, et al . Harrison's Principles of Internal Medicine, McGraw-Hill, NY; Gilman, et al . (eds. 1990) Goodman and Gilman' s: The Pharmacological Bases of Therapeutics, 8th Ed., Pergamon Press; Remington's Pharmaceutical Sciences, 17th ed. (1990), Mack Publishing Co., Easton, Penn; Langer (1990) Science 249:1527-1533; and Merck Index, Merck S- Co., Rahway, New Jersey.
- Antibodies to MIP-3 ⁇ proteins may be used for the identification or sorting of cell populations expressing MIP- 3 ⁇ protein, e.g., fibroblasts or Langerhans cells. Methods to sort such populations are well known the art, see, e.g., Melamed, et al . (1990) Flow Cytometry and Sorting Wiley-Liss, Inc., New York, NY; Shapiro (1988) Practical Flow Cytometry Liss, New York, NY; and Robinson, et al . (1993) Handbook of Flow Cytometry Methods Wiley-Liss, New York, NY.
- Populations of cells expressing the MIP-3 receptor, e.g., CCR6 can also be purified, e.g., using magnetic beads as described, e.g., m Bieva, et al . (1989) Ex . Hematol . 17:914-920; Hernebtub, et al . (1990) B ocorn . Chem. 1:411-418; Vaccaro (1990) Am. Biotechnol . Lab. 3:30.
- antisense nucleic acids may be used.
- antisense polynucleotides against the ligand encoding nucleic acids may function m a manner like ligand antagonists, and antisense against the receptor may function like receptor antagonists.
- antisense against the receptor may function like receptor antagonists.
- nucleic acids for the receptor may serve as agonists, increasing the numbers of receptor on the cell, thereby increasing cell sensitivity to ligand, and perhaps blocking the normal apoptotic signal described.
- the antibodies or binding compositions are useful m diagnosing diseases states which result skm disorders.
- Antibodies raised against a MIP-3 or CCR6 protein will also be useful to raise anti-idiotypic antibodies. These will be useful m detecting or diagnosing various immunological conditions related to expression of the respective antigens. Combinations of these signals may be also pursued.
- Lymphocyte migration assays are performed as previously described, e.g., m Bacon, et al . (1988) Br . J. Pharmacol. 95:966-974. Other trafficking assays are also available.
- An appropriate cell type is selected, e.g., hematopoietic cells, myeloid (macrophages , neutrophils, polymorphonuclear cells, etc.) or lymphoid (T cell, B cell, or NK cells), neural cells (neurons, neuroglia, oligodendrocytes, astrocytes, etc.), or stem cells, e.g., progenitor cells which differentiate to other cell types, e.g., gut crypt cells and undifferentiated cell types.
- hematopoietic cells myeloid (macrophages , neutrophils, polymorphonuclear cells, etc.) or lymphoid (T cell, B cell, or NK cells)
- neural cells neuroglia, oligodendrocytes, astrocytes, etc.
- stem cells e.g., progenitor cells which differentiate to other cell types, e.g., gut crypt cells and undifferentiated cell types.
- Chemokmes may also be assayed for activity m hemopoietic assays as described, e.g., by H. Broxmeyer. See Bellido, et al . (1995) J. Clinical Investigation 95:2886-2895; and Jilka, et al . (1995) Expt ' 1 Hematology 23:500-506. They may be assayed for angiogenic activities as described, e.g., by Streiter, et al . (1992) Am. J. Pathol . 141:1279-1284. Or for a role m inflammation. See, e.g., Wakefield, et al . (1996) J. Surgical Res. 64:26-31.
- Human primary cells including keratmocytes, melanocytes, and dermal fibroblasts are obtained from Clonetics and cultured according to the suppliers instructions.
- cytokme treatment cells are cultured with 10 ng/ml hTNF- plus 3 ng/ml hIL-l ⁇ (R&D Systems) m culture medium.
- Human T cells are purified from PBMCs using a T-cell enrichment column (R&D Systems) according to the manufacturers instructions .
- the human, mouse, or rat MIP-3 ⁇ sequence is readily available. See Table 1 and GenBank. Appropriate PCR primers or hybridization probes can be selected. Similarly, the human CCR6 , or others, can be readily isolated. See Table 2 and GenBank.
- RNAzol B TEL-TEST, Inc.
- Northern and Southern blots are hybridized for 16 hr at 65° C with 32P-labeled probes obtained by randomly priming (Prime-it; Stratagene) the full length inserts from mouse or human MIP-3 ⁇ or CCR6 clones.
- the MIP-3 ⁇ was identified from a cDNA library made from human monocytes activated with LPS and IFN- ⁇ , m the presence of ant ⁇ -IL-10. See, Rossi, et al . (1997) J. Immunology 158:1033-1036. Message of the chemokine has also been detected m pancreatic islet cells, fetal lung, and hepatic HEPG2 cells, suggesting a physiological role m inflammation or medical conditions m such organs/tissues.
- the gene is expressed m HL-60 (promyelocytic leukemia) ; S3 (HeLa cell) ; K562 (chronic myelogenous leukemia) ; MOLT-4 (lymphblastic leukemia); Raj l (Burkitt's lymphoma) ; SW480
- Tissue expression gave a positive signal m lymph node, appendix, peripheral blood lymphocytes, fetal liver, and fetal lung, suggesting a physiological role m inflammation or medical conditions m such organs/tissues; but no detectable signal m spleen, bone marrow, brain, and kidney.
- the mam transcript appears to be about 1.2 kb, with two additional transcript sizes m fetal lung RNA. Among the various tissues, transcript sizes of 1.8, 2.7, and 4.2 kb were detected.
- chemokine m inflammatory responses upon cell activation implicate this chemokine m inflammatory responses upon cell activation.
- the lymph nodes, appendix, and PBL are sites where inflammatory processes take place.
- the MIP-3 ⁇ may exert its effects on monocytes and cells involved m inflammatory events.
- Other structural features implicate this chemokine m eosmophil and lung physiology, e.g., asthma indications.
- an antagonist of the chemokine e.g., an antibody, may be important for treatment of asthmatic conditions.
- IL-10 appears to inhibit MIP-3 expression.
- the human MIP-3 is a ligand for the CCR6.
- the CCR6 was isolated from eosmophil cDNA, and observations have been made that eosmophils migrate to MIP-3 ⁇ m vitro. See, e.g., Greaves, et al . (1997) J . Exp . Med . 186:837-844; Liao, et al . (1997) Biochem. Biophys . Res. Commun. 236:212-217; and Liao, et al . (1998) J. Immunol. 162:186-194.
- MIP-3 ⁇ interaction with the CCR6 is important m recruitment of eosmophils, as occurs with the eotaxm ligand and the CCR3.
- antagonists of the MIP-3 interaction with the CCR6 will likely be useful m inhibiting eosmophilia, particularly m the lung, or lung inflammation. These may accompany asthmatic or other pulmonary conditions.
- the specific upregulation of the pair m inflamed skm suggests a role m skm immunity.
- the CCR6 was isolated from a cDNA library made from a dendritic cell cDNA library. It appears to be expressed m certain T cells, spleen cell subsets, NK cells, and other cell populations enriched m dendritic cells, including CDla + , CD14 + , and CDlAa + cells. It did not give a detectable signal m TF1, Jurkat, MRC5 , JY, or U937 cell lines. Quantitative PCR methods have been applied, e.g.,
- TAQMANTM High levels of CCR6 cDNA was detected m libraries made from peripheral blood mononuclear cells, resting; T cell, THO clone Mot 72, resting; T cell, TH1 clone HY06, anergic; T cell clones, pooled, resting; T cell ⁇ clones, resting; Splenocytes, resting; Splenocytes, activated; B cell EBV lines, resting; NK 20 clones pooled, resting; NK cell clone, NKA6 ; NK cytotoxic clone, resting; NK cell clone, NK non cytotox; monocytes, LPS, ⁇ lFN, anti -IL-10, 4+16 hr; monocytes, LPS, ⁇ lFN, IL-10, 4+16 hr ; DC 70% CDla+, ex CD34+ GM-CSF, TNF ⁇ , activated 1 hr; DC 70% CDla+,
- MIP-3 ⁇ Being found on dendritic cells, its ligand, including the MIP-3 ⁇ , may be important m attracting appropriate cells for the initiation of an immune response. MIP-3 ⁇ has been shown to be a very potent chemoattractant for dendritic cells. Significant roles of the ligand and receptor in skin physiology are suggested. The receptor may be also present in other cells important in such responses.
- Recombinant mouse MIP-3 ⁇ is produced m E. coli and purified, e.g., as previously described for other chemokmes. Hed ⁇ ck, et al . (1998) Blood 91:4242-4247. Total human T cells m DMEM, pH 6.9, 1% bovme serum albumin, were added to the top chamber of 3 ⁇ m pore polycarbonate Transwell culture insert (Costar) and incubated with the indicated concentrations of purified chemokine the bottom chamber for 3 h. The number of migrating cells of each subtype is determined by multi-parameter flow cytometry using fluorochrome conjugated antibodies.
- a known number of 15 ⁇ m microsphere beads (Bangs Laboratories, Fishers, IN) is added to each sample before analysis m order to determine the absolute number of migrating cells.
- Chemotaxis assays are performed with purified human peripheral -blood T cells and/or skm-hom g T cells.
- Other cell types express the CCR6 , e.g., T cells, B cells, DC cells, and granulocyte cells, e.g., neutrophils and/or eosmophils.
- Recombinant murine MIP-3 ⁇ should have effects on the cell types expressing CCR6.
- the MIP-3 ⁇ and CCR6 expression levels are very low m normal skm samples, but are highly upregulated m inflamed skm tissues.
- Appropriate mammals are immunized with appropriate amounts, e.g., of MIP-3 ⁇ or MIP-3 ⁇ gene transfected cells, e.g., mtrape ⁇ toneally every 2 weeks for 8 weeks. Similar methods may be used to produce antibodies which bind to CCR6 , e.g., purified CCR6 , polypeptides, or transfected cells expressing the receptor may be used. Typically, rodents are used, though other species should accommodate production of selective and specific antibodies. The final immunization is given intravenously (IV) through the tail vein. Generic polyclonal antibodies may be collected.
- IV intravenously
- monoclonal antibodies can be produced. For example, four days after the IV injection, the spleen is removed and fused to SP2/0 and NS1 cells. HAT resistant hyb ⁇ domas are selected, e.g., using a protocol designed by Stem Cell Technologies (Vancouver, BC) . After 10 days of HAT selection, resistant foci are transferred to 96 well plates and expanded for 3 days. Antibody containing supernatants are analyzed, e.g., by FACS for binding to NIH3T3/surface MIP-3 ⁇ transfectants . Many different MIP-3 ⁇ mAbs are typically produced. Those antibodies may be isolated and modified, e.g., by labeling or other means as is standard the art.
- MIP-3 ⁇ responsive cells may be identified using the reagents described herein. For example, cells which are chemoattracted towards MIP-3 ⁇ may be purified from other cells by collecting those cells which traverse towards MIP-3 ⁇ . Such chemotaxis may be to a source of chemokine, or may be across a porous membrane or other substrate. See above, m the microchemotaxis assay.
- responsive cells may be identified by expression of the receptor, e.g., CCR6 , as provided herein.
- CCR6 the receptor for sorting cells likely to respond to MIP-3 ⁇ .
- the marker may be used to deplete CCR6 bearing cells, e.g., by magnetic depletion or toxic conjugates.
- a biological sample e.g., blood, tissue biopsy sample, lung or nasal lavage, skm punch, is obtained from an individual suffering from a skm related disorder.
- MIP-3 ⁇ responsive cell analysis is performed, e.g., by FACS analysis, or similar means.
- MIP-3 ⁇ Antagonists Various antagonists of MIP-3 ⁇ are made available. For example, antibodies against the chemokine itself may block the binding of ligand to its receptor, thereby serving as a direct receptor antagonist. Other antagonists may function by blocking the binding of ligand to receptor, e.g., by binding to the receptor m a way to preclude the possibility of binding of ligand. Other antagonists, e.g., mutem antagonists or aptamers, may bind to the receptor without signaling, thereby blocking a true agonist from binding. Many of these may serve to block the signal transmitted to target cells, specifically MIP-3 ⁇ - responsive cells. These may be skm cells, including Langerhans, fibroblasts, or keratmocytes.
- Standard mutagenesis analysis is performed, e.g., by generating many different variants at determined positions, e.g., at the positions identified above, and evaluating biological activities of the variants. This may be performed to the extent of determining positions which modify activity, or to focus on specific positions to determine the residues which can be substituted to either retain, block, or modulate biological activity.
- analysis of natural variants can indicate what positions tolerate natural mutations. This may result from populational analysis of variation among individuals, or across strains or species. Samples from selected individuals are analyzed, e.g., by PCR analysis and sequencing. This allows evaluation of population polymorphisms.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00908238A EP1149113A1 (en) | 1999-02-03 | 2000-02-02 | Use of agonists or antagonists of mip-3a in therapy |
JP2000597318A JP2002540068A (en) | 1999-02-03 | 2000-02-02 | Use of MIP-3A agonists or antagonists in therapy |
AU29622/00A AU2962200A (en) | 1999-02-03 | 2000-02-02 | Use of agonists or antagonists of mip-3a in therapy |
CA002362091A CA2362091A1 (en) | 1999-02-03 | 2000-02-02 | Use of agonists or antagonists of mip-3a in therapy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24428199A | 1999-02-03 | 1999-02-03 | |
US09/244,281 | 1999-02-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000046248A1 true WO2000046248A1 (en) | 2000-08-10 |
Family
ID=22922114
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/000511 WO2000046248A1 (en) | 1999-02-03 | 2000-02-02 | Use of agonists or antagonists of mip-3a in therapy |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1149113A1 (en) |
JP (1) | JP2002540068A (en) |
AU (1) | AU2962200A (en) |
CA (1) | CA2362091A1 (en) |
WO (1) | WO2000046248A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001017558A2 (en) * | 1999-09-08 | 2001-03-15 | Schering Corporation | Novel uses of mammalian ccr6 receptors and related reagents |
WO2001038352A2 (en) * | 1999-11-24 | 2001-05-31 | Schering Corporation | Methods of inhibiting metastasis |
WO2004084931A1 (en) * | 2003-03-24 | 2004-10-07 | Tap Pharmaceuticals Products Inc. | Use of chemokine receptor agonists for stem cell transplantation |
JP2005502723A (en) * | 2001-09-20 | 2005-01-27 | シェーリング コーポレイション | Chemokines as adjuvants of immune responses |
US6949243B1 (en) | 1999-11-24 | 2005-09-27 | Schering Corporation | Methods of inhibiting metastasis |
EP1600165A1 (en) * | 2003-03-04 | 2005-11-30 | Takeda Pharmaceutical Company Limited | Medicinal use of mip-3alpha inhibitor and method of screening brain/nerve cell protective agent |
US7375192B2 (en) * | 2002-05-01 | 2008-05-20 | Human Genome Sciences, Inc. | Antibodies that specifically bind to chemokine beta-4 |
EP2360277A1 (en) * | 2006-05-03 | 2011-08-24 | Geisinger Clinic | Methods for diagnosing and predicting non-alcoholic steatohepatitis (NASH) |
EP2640744A2 (en) * | 2010-11-19 | 2013-09-25 | Toshio Imai | Neutralizing anti-ccl20 antibodies |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5504003A (en) * | 1994-03-08 | 1996-04-02 | Human Genome Sciences, Inc. | Macrophage inflammatory protein-3 and -4 |
WO1998001557A2 (en) * | 1996-07-05 | 1998-01-15 | Schering Corporation | Mammalian chemokine reagents |
WO1999020759A1 (en) * | 1997-10-22 | 1999-04-29 | Genetics Institute, Inc. | Chemokines with amino-terminal modifications |
WO2000009151A1 (en) * | 1998-08-17 | 2000-02-24 | Schering Corporation | Regulation of dendritic cell trafficking |
-
2000
- 2000-02-02 JP JP2000597318A patent/JP2002540068A/en not_active Withdrawn
- 2000-02-02 EP EP00908238A patent/EP1149113A1/en not_active Withdrawn
- 2000-02-02 AU AU29622/00A patent/AU2962200A/en not_active Abandoned
- 2000-02-02 WO PCT/US2000/000511 patent/WO2000046248A1/en active Search and Examination
- 2000-02-02 CA CA002362091A patent/CA2362091A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5504003A (en) * | 1994-03-08 | 1996-04-02 | Human Genome Sciences, Inc. | Macrophage inflammatory protein-3 and -4 |
WO1998001557A2 (en) * | 1996-07-05 | 1998-01-15 | Schering Corporation | Mammalian chemokine reagents |
WO1999020759A1 (en) * | 1997-10-22 | 1999-04-29 | Genetics Institute, Inc. | Chemokines with amino-terminal modifications |
WO2000009151A1 (en) * | 1998-08-17 | 2000-02-24 | Schering Corporation | Regulation of dendritic cell trafficking |
Non-Patent Citations (6)
Title |
---|
BABA M ET AL: "IDENTIFICATION OF CCR6, THE SPECIFIC RECEPTOR FOR A NOVEL LYMPHOCYTE-DIRECTED CC CHEMOKINE LARC", JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 272, no. 23, 6 September 1997 (1997-09-06), pages 14893 - 14898, XP002055488, ISSN: 0021-9258 * |
GREAVES D R ET AL: "CCR6, A CC CHEMOKINE RECEPTOR THAT INTERACTS WITH MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA AND IS HIGHLY EXPRESSED IN HUMAN DENDRITIC CELLS", JOURNAL OF EXPERIMENTAL MEDICINE,JP,TOKYO, vol. 186, no. 6, 15 September 1997 (1997-09-15), pages 837 - 844, XP000199997, ISSN: 0022-1007 * |
HIESHIMA K ET AL: "MOLECULAR CLONING OF A NOVEL HUMAN CC CHEMOKINE LIVER AND ACTIVATION-REGULATED CHEMOKINE (LARC) EXPRESSES IN LIVER. CHEMOTACTIX ACTIVITY FOR LYMPHOCYTES AND GENE LOCALIZATION ON CHROMOSOME", JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 272, no. 9, 28 February 1997 (1997-02-28), pages 5846 - 5853, XP002055489, ISSN: 0021-9258 * |
POWER C A ET AL: "CLONING AND CHARACTERIZATION OF A SPECIFIC RECEPTOR FOR THE NOVEL CC CHEMOKINE MIP-3ALPHA FROM LUNG DENDRITIC CELLS", JOURNAL OF EXPERIMENTAL MEDICINE,JP,TOKYO, vol. 186, no. 6, 15 September 1997 (1997-09-15), pages 825 - 835, XP000198408, ISSN: 0022-1007 * |
ROSSI D L ET AL: "IDENTIFICATION THROUGH BIOINFORMATICS OF TWO NEW MACROPHAGE PROINFLAMMATORY HUMAN CHEMOKINES MIP-3ALPHA AND MIP-3BETA1,2", JOURNAL OF IMMUNOLOGY,US,THE WILLIAMS AND WILKINS CO. BALTIMORE, vol. 158, no. 3, 1 February 1997 (1997-02-01), pages 1033 - 1036, XP000198409, ISSN: 0022-1767 * |
YOSHIE O ET AL: "NOVEL LYMPHOCYTE-SPECIFIC CC CHEMOKINES AND THEIR RECEPTORS", JOURNAL OF LEUKOCYTE BIOLOGY,US,FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL, vol. 62, no. 5, 1 November 1997 (1997-11-01), pages 634 - 644, XP002055491, ISSN: 0741-5400 * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001017558A3 (en) * | 1999-09-08 | 2001-09-27 | Schering Corp | Novel uses of mammalian ccr6 receptors and related reagents |
WO2001017558A2 (en) * | 1999-09-08 | 2001-03-15 | Schering Corporation | Novel uses of mammalian ccr6 receptors and related reagents |
US7521045B2 (en) | 1999-11-24 | 2009-04-21 | Schering Corporation | Methods of inhibiting metastasis |
WO2001038352A2 (en) * | 1999-11-24 | 2001-05-31 | Schering Corporation | Methods of inhibiting metastasis |
WO2001038352A3 (en) * | 1999-11-24 | 2001-10-18 | Schering Corp | Methods of inhibiting metastasis |
US6949243B1 (en) | 1999-11-24 | 2005-09-27 | Schering Corporation | Methods of inhibiting metastasis |
EP2261256A3 (en) * | 1999-11-24 | 2011-03-02 | Schering Corporation | Methods of inhibiting metastasis |
JP2005502723A (en) * | 2001-09-20 | 2005-01-27 | シェーリング コーポレイション | Chemokines as adjuvants of immune responses |
US7943741B2 (en) | 2002-05-01 | 2011-05-17 | Human Genome Sciences, Inc. | Antibodies that specifically bind to chemokine β-4 |
US7375192B2 (en) * | 2002-05-01 | 2008-05-20 | Human Genome Sciences, Inc. | Antibodies that specifically bind to chemokine beta-4 |
EP1600165A4 (en) * | 2003-03-04 | 2007-06-27 | Takeda Pharmaceutical | Medicinal use of mip-3alpha inhibitor and method of screening brain/nerve cell protective agent |
EP1600165A1 (en) * | 2003-03-04 | 2005-11-30 | Takeda Pharmaceutical Company Limited | Medicinal use of mip-3alpha inhibitor and method of screening brain/nerve cell protective agent |
WO2004084931A1 (en) * | 2003-03-24 | 2004-10-07 | Tap Pharmaceuticals Products Inc. | Use of chemokine receptor agonists for stem cell transplantation |
EP2360277A1 (en) * | 2006-05-03 | 2011-08-24 | Geisinger Clinic | Methods for diagnosing and predicting non-alcoholic steatohepatitis (NASH) |
EP2640744A2 (en) * | 2010-11-19 | 2013-09-25 | Toshio Imai | Neutralizing anti-ccl20 antibodies |
EP2640744A4 (en) * | 2010-11-19 | 2014-05-28 | Eisai R&D Man Co Ltd | Neutralizing anti-ccl20 antibodies |
US9133273B2 (en) | 2010-11-19 | 2015-09-15 | Eisai R&D Management Co., Ltd. | Nucleic acids encoding neutralizing anti-CCL20 antibodies |
US9809647B2 (en) | 2010-11-19 | 2017-11-07 | Eisai R&D Management Co., Ltd. | Neutralizing anti-CCL20 antibodies |
Also Published As
Publication number | Publication date |
---|---|
EP1149113A1 (en) | 2001-10-31 |
JP2002540068A (en) | 2002-11-26 |
CA2362091A1 (en) | 2000-08-10 |
AU2962200A (en) | 2000-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zabel et al. | Human G protein–coupled receptor GPR-9-6/CC chemokine receptor 9 is selectively expressed on intestinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine–mediated chemotaxis | |
US7521045B2 (en) | Methods of inhibiting metastasis | |
US6245332B1 (en) | Modulation of systemic memory T cell trafficking | |
US20030092881A1 (en) | Mammalian receptor proteins; related reagents and methods | |
US20120231003A1 (en) | Ox2 Receptor Homologs | |
EP1079847B1 (en) | Osteoporosis treatment | |
CA2389979C (en) | Methods of inhibiting metastasis | |
JP2000514295A (en) | Mammalian chemokine reagent | |
EP1149113A1 (en) | Use of agonists or antagonists of mip-3a in therapy | |
US6645491B1 (en) | Method for treating inflammatory conditions using an antibody to MIP-3α | |
CA2309761A1 (en) | Th2 cell depletion; compositions; methods | |
EP1140174B1 (en) | Antagonist antibodies of cutaneous t cell-attracting chemokine (ctack) or vasoactive intestinal contractor (vic) chemokines | |
US6692922B2 (en) | Method for identifying agents which modulate chemokine “MEC”-induced functions of CCR3 | |
US20100068763A1 (en) | Mammalian chemokines; receptors; reagents; uses | |
KR100870296B1 (en) | A Fusion Protein | |
US6824781B2 (en) | Method of impairing movement of a CLA + memeory T-cell within or to the skin of a mammal by administering a CTACK antagonist | |
MXPA01007938A (en) | Use of agonists or antagonists of mip-3a in therapy | |
US6416954B1 (en) | Modulating Th2 cell levels via vMIP-I/CCR8 interaction | |
EP1806146A1 (en) | Agonists or antagonists of cutaneous T cell-attracting chemokine (CTACK) or vasoactive intestinal contractor (VIC) chemokines | |
MXPA01006612A (en) | Agonists or antagonists of cutaneous t cell-attracting chemokine (ctack) or vasoactive intestinal contractor (vic) chemokines | |
Laning | Biochemical and functional characterization of the murine beta-chemokine, TCA3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA UZ VN YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2362091 Country of ref document: CA Ref country code: CA Ref document number: 2362091 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 597318 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/007938 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000908238 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000908238 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000908238 Country of ref document: EP |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) |